Tandem Diabetes (TNDM) Form 4: 1,749-share RSU conversion by director
Rhea-AI Filing Summary
SEC Form 4 filed on 06/18/2025 reveals that Tandem Diabetes Care, Inc. (TNDM) director Myoungil Cha acquired 1,749 shares of common stock on 06/16/2025 through the vesting and settlement of previously granted restricted stock units (RSUs) under the company’s 2013 Stock Incentive Plan. The conversion, reported with transaction code “M,” was executed at $0 cost to the insider and involved no open-market purchase or sale.
Following the transaction, Cha’s direct beneficial ownership rose from 11,950 to 13,699 shares. The RSU grant was originally awarded on 06/15/2022 and vests in three equal annual installments; the reported shares represent the second installment, with additional tranches scheduled for future anniversaries, subject to plan terms.
Key takeaways:
- Insider ownership increase: +1,749 shares, signalling continued alignment with shareholder interests.
- Routine equity compensation: Transaction stems from standard RSU vesting, not discretionary market activity.
- No cash proceeds or sales: Neutral impact on near-term share flow and insider liquidity.
Positive
- Insider ownership increased by 1,749 shares, suggesting continued equity alignment with shareholders.
Negative
- None.
Insights
TL;DR – Routine RSU vesting adds 1,749 shares to director’s holdings; market impact minimal.
The filing shows an automatic conversion of RSUs, increasing Cha’s stake to 13,699 shares. Because no shares were sold and the exercise price was $0, the transaction is non-dilutive beyond the ordinary course of equity compensation. Such activity is typical for directors and is unlikely to alter near-term supply-demand dynamics or valuation multiples. Investors may view the retention of shares as a mild positive signal, but the size—well below 1% of float—keeps overall impact neutral.
TL;DR – Standard plan-based vesting; supports alignment but not materially significant.
This Form 4 reflects compliance with Tandem Diabetes Care’s 2013 Stock Incentive Plan. The director did not elect a 10b5-1 sale program and retained the newly issued shares, which can be interpreted as confidence in the firm. However, without additional buying or sizeable ownership changes, governance implications remain neutral. No red flags regarding timing or disclosure are evident.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 1,749 | $0.00 | -- |
| Exercise | Common Stock | 1,749 | $0.00 | -- |
Footnotes (1)
- Awarded on June 15, 2022 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan). Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. The total number of shares subject to the RSU will vest over a period of three years in equal annual installments on the anniversary of the grant, subject to the terms of the 2013 Plan.
